Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration

被引:24
|
作者
Bellmann, R [1 ]
Egger, P
Djanani, A
Wiedermann, CJ
机构
[1] Univ Innsbruck, Med Intens Care Res Lab, Clin Pharmacokinet Unit, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, Intens Care Unit, A-6020 Innsbruck, Austria
关键词
amphotericin B lipid complex; ABLC; abelcet; lipid-formulated amphotericin B; pharmacokinetics; continuous veno-venous haemofiltration;
D O I
10.1016/j.ijantimicag.2003.05.014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pharmacokinetics of amphotericin B lipid complex (ABLC) was determined in two critically ill patients requiring continuous veno-venous haemofiltration (CVVH) because of acute renal failure. ABLC was administered at a mean daily dose of 4.94 mg/kg for suspected invasive mycosis. Mean C-max was 0.56 mug/ml, the mean AUC(0-24 h) was 7.46 mg h/I, V-SS 9.131/kg, and t(1/2) was 13.21 h. The haemofilter clearance accounted about 20% of the total ABLC clearance. In one patient sampling was repeated after CVVH had been discontinued. The concentration-time profiles were very similar on and off haemofiltration. Data on our two patients suggest, that pharmacokinetics of ABLC is not significantly affected by CVVH and that ABLC can be administered at the standard doses during CVVH. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:80 / 83
页数:4
相关论文
共 50 条
  • [42] Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration
    Thomson, AH
    Shankland, G
    Clareburt, C
    Binning, S
    INTENSIVE CARE MEDICINE, 2002, 28 (07) : 999 - 999
  • [43] Comparison of two different types of catheter for venous access in continuous veno-venous haemofiltration
    Wybo, R
    De Backer, D
    Vanderwaelen, C
    Maerschaelck, N
    Demarré, F
    Vincent, JL
    INTENSIVE CARE MEDICINE, 2001, 27 : S295 - S295
  • [44] Population pharmacokinetics of colistin sulfate in patients on continuous veno-venous hemodiafiltration
    Huang, Tianmin
    Luo, Yilin
    Wu, Yun
    Niu, Lulu
    Xiao, Yang
    Wu, Tingqing
    Chen, Xin
    Liu, Yongjun
    Lu, Jiejiu
    Zhu, Donglan
    Liu, Taotao
    SCIENCE PROGRESS, 2025, 108 (01)
  • [45] Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration
    Hansen, E
    Bucher, M
    Jakob, W
    Lemberger, P
    Kees, F
    INTENSIVE CARE MEDICINE, 2001, 27 (02) : 371 - 375
  • [46] Amikacin Pharmacokinetics During Continuous Veno-Venous Hemodialysis
    Lam S.W.
    Bauer S.R.
    Infectious Diseases and Therapy, 2013, 2 (2) : 217 - 226
  • [47] Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure
    Valtonen, M
    Tiula, E
    Backman, JT
    Neuvonen, PJ
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (05) : 701 - 704
  • [48] Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration
    Ernil Hansen
    Michael Bucher
    Wolfgang Jakob
    Peter Lemberger
    Frieder Kees
    Intensive Care Medicine, 2001, 27 : 371 - 375
  • [49] Continuous veno-venous haemofiltration versus continuous veno-venous haemodialysis in severe lithium self-poisoning:: a toxicokinetics study in an intensive care unit
    Hazouard, E
    Ferrandière, M
    Rateau, H
    Doucet, O
    Perrotin, D
    Legras, A
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (06) : 1605 - 1606
  • [50] AMIKACIN PHARMACOKINETICS DURING CONTINUOUS VENO-VENOUS HEMODIALYSIS
    Lam, Simon
    Bauer, Seth
    CRITICAL CARE MEDICINE, 2010, 38 (12) : U232 - U232